A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
T-cell Non-Hodgkin's lymphomas are a group of cancers that are usually treated with
chemotherapy, radiation therapy, or occasionally surgery. T-cell lymphomas are relatively
uncommon and therefore not well studied. Treatment approaches are patterned after the more
common B-cell lymphomas. T-cell lymphomas are more likely to relapse following standard
therapy than are B-cell lymphomas. New therapies are needed for T-cell lymphomas. In this
study, we will administer the drug called lenalidomide as a pill to patients with T-cell
lymphoma. The goals are to determine if the drug can induce regression of the cancer, and to
determine if the treatment is well tolerated in this patient group. This study will take
place at six cancer centres across Canada.